Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

Author:Wiendl, Heinz   De Stefano, Nicola   Barkhof, Frederik   Montalban, Xavier   Achiron, Anat   Derfuss, Tobias   Chan, Andrew   Hodgkinson, Suzanne   Prat, Alexandre   Leocani, Letizia   Schmierer, Klaus   Sellebjerg, Finn   Vermersch, Patrick   Jin, Hulin   Jarvinen, Elina   Chudecka, Anita   Gardner, Lidia   

Session Name:S16: MS Clinical Trials and Therapeutics  

Topic:MS and Inflammatory Disease  

Program Number:S16.006  

Author Institution:University of Muenster, Muenster, Germany  Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy  VU University Medical Center, Amsterdam, Netherlands  Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain  Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel  University Hospital Basel, Basel, Switzerland  Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland  Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, Australia  Université de Montréal, Montreal, QC, Canada  Experimental Neurophysiology Unit, Vita-Salute San Raffaele University, Milan, Italy  The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom  Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark  Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France  the healthcare business of Merck KGaA, Darmstadt, Germany, Darmstadt, Germany  Cytel Inc. Geneva, Switzerland, Geneva, Switzerland  EMD Serono, Billerica, MA, USA, Billerica, MA  

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study

Author:Bermel, Robert   Hartung, Hans-Peter   Brochet, Bruno   Benedict, Ralph   Berger, Thomas   Carroll, William   Vollmer, Timothy   Holmoy, Trygve   Karabudak, Rana   Killestein, Joep   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Wuerfel, Jens   Kuenzel, Thomas   Kadner, Karen   Kulyk, Inessa   Freedman, Mark   

Session Name:S46: MS Therapeutics and Clinical Decision Making  

Topic:MS and Inflammatory Disease  

Program Number:S46.004  

Author Institution:Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Deptartment of Neurology, Heinrich-Heine-University Düsseldorf, Germany, Dusseldorf, Germany  Université de Bordeaux, Neurocentre Magendie INSERM, Bordeaux, France, Bordeaux, France  Jacobs School of Medicine and Biomedical Sciences, Department of Neurology, University of Buffalo, NY, USA, Buffalo, NY  Dept. of Neurology, Medical University of Vienna, Vienna, Austria  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA, Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute Ottawa, ON, Canada., Ottawa, ON, Canada